ASH 2024: Top abstracts in lymphoma and CLL

Abstract #

Title

Speaker

Time (PT)

Indolent and mantle cell NHL

235

Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, ENRICH

David John Lewis

14:00

240

Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized TRIANGLE trial by the European MCL network

Martin Dreyling

15:15

338

Randomized phase III study of watchful waiting vs. rituximab as first-line treatment in patients with advanced stage low tumor burden follicular lymphoma: JCOG1411/FLORA study

Noriko Fukuhara

16:15

339

Impact of minimal residual disease analysis in the era of rituximab maintenance in follicular lymphoma: Data from "FOLL12" phase III trial of the Fondazione Italiana Linfomi

Simone Ferrero

16:30

340

Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial

Lorenzo Falchi

16:45

342

Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the EPCORE NHL-2 trial

Lorenzo Falchi

17:15

1626

High-risk subgroups and MRD: An updated analysis of the phase III ECHO trial of acalabrutinib with bendamustine/rituximab in previously untreated mantle cell lymphoma

Martin Dreyling

17:30 (poster session)

Hodgkin's lymphoma

1667

Potential delayed immune-related adverse events in patients treated with frontline pembrolizumab + AVD for classic Hodgkin lymphoma

Thomas Kuczmarski

17:30 (poster session)

1668

Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma – international, multi-center real-world experience

Efrat Luttwak

17:30 (poster session)

2346

Estimation of health state utility values for patients undergoing first-line treatment of advanced-stage classical Hodgkin lymphoma in the HD21 trial

Ajibade Ashaye

17:30 (poster session)

Aggressive B-cell non-Hodgkin lymphoma

91

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang

09:30

111

Real-world outcomes with bispecific T-cell engagers (REALBiTE) for relapsed or refractory large B-cell Lymphoma: A Multi-center, retrospective cohort study

Taylor R. Brooks

10:00

72

Circulating tumor DNA (ctDNA) as an early outcome predictor in patients (pts) with second-line (2L) large B-cell lymphoma (LBCL) after lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) treatment (tx) from the phase III, randomized TRANSFORM study

Ash A. Alizadeh

10:45

114

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

Evgenii Shumilov

10:45

386

Safety and efficacy of chimeric antigen receptor T-cell therapy in octogenarian patients (aged ≥ 80) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Dasom Lee

16:15

Chronic lymphocytic leukemia/small lymphocytic lymphoma

1867

Multicenter phase IItrial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400)

Jacob D. Soumerai

17:30 (poster session)

1869

Consistently high 5.5-year progression-free survival (PFS) rates in patients with and without bulky baseline lymphadenopathy ≥5 cm are associated with high undetectable minimal residual disease (uMRD4) rates after first-line treatment with fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase II CAPTIVATE Study

William G. Wierda

17:30 (poster session)

Abstract #

Title

Speaker

Time (PT)

Indolent and mantle cell NHL

3031

Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase III ASPEN study: A report from the zanubrutinib extension study

Shirley D’Sa

18:00 (poster session)

3034

Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase II ELARA 4-year update

Catherine Thieblemont

18:00 (poster session)

T-cell lymphoma

463

Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma

Alison Moskowitz

09:30

466

Health-related quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma treated by lacutamab: Patient-reported outcomes from the phase II TELLOMAK trial

Pierluigi Porcu

10:15

468

Randomized phase II trial of the anti-PD-L1 monoclonal antibody durvalumab plus lenalidomide versus single-agent durvalumab in patients with refractory/advanced cutaneous T cell lymphoma

Christiane Querfeld

10:45

Hodgkin's lymphoma

460

Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma

Jeremy S. Abramson

10:15

461

Omission of bleomycin in limited stage classic Hodgkin lymphoma patients with a negative PET scan following 2 cycles of ABVD is associated with comparable outcomes and reduced pulmonary toxicity

Jiayu Yang

10:30

462

Pembrolizumab in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma (cHL) and slow early response to front-line chemotherapy: Updated results from the phase II KEYNOTE-667 study

Lisa Giulino Roth

10:45

569

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Alison Moskowitz

13:00

3045

Brentuximab vedotin (BV) and nivolumab (nivo) for untreated patients with Hodgkin lymphoma (HL): Long-term results

Bruce D. Cheson

18:00 (poster session)

3053

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Robert Stuver

18:00 (poster session)

Aggressive B-cell non-Hodgkin lymphoma

469

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

Gilles Salles

09:30

470

Real-world (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): First results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry

Maria Silvina Odstrcil Bobillo

09:45

526

Real-world early outcomes of second-line axicabtagene ciloleucel (axi-cel) therapy in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Dasom (Caroline) Lee

10:15

527

Real-world trends of cytokine release syndrome and neurologic events, and pattern of their management among patients receiving axicabtagene ciloleucel for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the US: A CIBMTR report

Jiasheng Wang

10:30

575

Outcomes of primary mediastinal B-cell lymphoma patients treated with a PET-guided strategy in the randomized phase III gained study conducted by Lysa

Vincent Camus

13:00

577

Final Analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma

Catherine S. Diefenbach

12:00

607

Tisagenlecleucel for the management of patients with relapsed/refractory diffuse large B-cell lymphoma: An interim report of the European post-authorisation safety study conducted by EBMT

Christian Chabannon

12:00

579

Golcadomide (GOLCA) plus R-CHOP has high minimal residual disease (MRD) negativity across high-risk, untreated aggressive B-cell lymphoma (a-BCL)

Jason R. Westin

12:30

581

Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: Long-term results from the EPCORE NHL-2 TRIAL

Lorenzo Falchi

13:00

582

A randomized phase II, investigator-led trial of glofitamab-R-CHOP or glofitamab-polatuzumab vedotin-R-CHP (COALITION) in younger patients with high burden, high-risk large B-cell lymphoma demonstrates safety, uncompromised chemotherapy intensity, a high rate of durable remissions, and unique FDG-PET response characteristics

Adrian Minson

13:15

2336

Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

Varun Iyengar

17:30 (poster session)

Chronic lymphocytic leukemia/small lymphocytic lymphoma

584

Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : Final results of the ERADIC trial from the Filo group

Anne Sophie Michallet

12:15

585

IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: Report of the UK NCRI FLAIR study

Talha Munir

12:30

3249

Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study

Mazyar Shadman

18:00 (poster session)

3251

Acalabrutinib versus chlorambucil plus rituximab in patients with previously untreated chronic lymphocytic leukemia: A randomized, multicenter, open-label, phase III study

Lugui Qiu

18:00 (poster session)

Abstract #

Title

Speaker

Time (PT)

Indolent and mantle cell NHL

859

Bortezomib in combination with ibrutinib/rituximab is a highly effective and well tolerated first – line treatment for Waldenström’s macroglobulinemia: results of the multicenter phase II trial (ECWM-2) of the European Consortium for Waldenström’s macroglobulinemia

Christian Buske

14:45

861

Iopofosine I 131 in previously treated patients with Waldenström macroglobulinemia (WM): Efficacy and safety results from the international, multicenter, open-label phase II study (CLOVER-WaM™)

Sikander Ailawadhi

15:15

862

Efficacy and safety of odronextamab in relapsed/refractory marginal zone lymphoma (R/R MZL): Data from the R/R MZL cohort in the ELM-2 study

Tae Min Kim

15:30

864

5-year follow-up analysis from ZUMA-5: A phase II trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma

Sattva S. Neelapu

16:00

4388

Five-year outcomes of patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 cohorts 1 and 2

Michael Wang

18:00 (poster session)

Aggressive B-cell non-Hodgkin lymphoma

865

Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study

Michael J. Dickinson

14:45

866

Efficacy and safety of odronextamab monotherapy in patients (pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study

Matthew Matasar

15:00

867

EPCORE DLBCL-3 first disclosure: Fixed-duration epcoritamab monotherapy in older (≥75 y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma

Franck Morschhauser

15:15

869

Longer follow-up of golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMoD™) agent ± rituximab (RTX), in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Jean-Marie Michot

15:45

957

BMS-986458 a potential first-in-class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi-modal anti-tumor efficacy for the treatment of B-cell non-Hodgkin’s lymphoma

Lynda Groocock

17:00

988

Glofitamab in combination with polatuzumab vedotin maintains durable responses and a manageable safety profile in patients with heavily pre-treated relapsed/refractory (R/R) large B-cell lymphoma (LBCL) including high-grade B-cell lymphoma (HGBCL): Extended follow-up of a phase Ib/II study

Martin Hutchings

17:15

4483

Outcomes in older patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study

Nancy L. Bartlett

18:00 (poster session)

4474

A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign

Pallawi Torka

18:00 (poster session)

5132

Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the phase III STARGLO study

Gareth P. Gregory

18:00 (poster session)

Chronic lymphocytic leukemia/small lymphocytic lymphoma

883

Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of EPCORE CLL-1

Alexey Danilov

14:45

886

BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Jeff P. Sharman

15:30

887

Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary results from the open-label, phase I/II TRANSCEND CLL 004 study

William G. Wierda

15:45

1009

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase III AMPLIFY trial

Jennifer R. Brown

16:30

1010

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Meghan C. Thompson

16:45

1011

Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL)

Nitin Jain

17:00

4633

Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Updated follow-up of TRANSCEND CLL 004

Tanya Siddiqi

18:00 (poster session)

Abstract #

Title

Speaker

Time (PT)

Indolent and mantle cell NHL

LBA1

Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase III study (inMIND)

Laurie H. Sehn

07:30

LBA6

Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): Initial report from the ECOG-ACRIN EA4151 phase III randomized trial

Timothy S. Fenske

07:30